Form 4: Terns Pharmaceuticals Director Jill M. Quigley Executes Stock Options and Sells Shares

Director Jill M. Quigley of Terns Pharmaceuticals exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 15, 2024, Jill M. Quigley, a director of Terns Pharmaceuticals, exercised stock options to acquire 14,365 shares of common stock at a price of $1.82 per share and sold the same amount at a weighted average price of $10.0007 per share.
• On July 16, 2024, Quigley exercised options for another 400 shares at $1.82 and sold them at $10 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 18, 2024.
• Following these transactions, Quigley directly owns 30,000 shares of common stock and 17,235 stock options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates